Category: ACN Newswire

香港，2025年8月22日 - (亞太商訊 via SeaPRwire.com) - 中聯發展控股集團有限公司（下稱「本公司」；聯交所編號：0264）欣然宣布，已簽訂最終協議收購香港金融科技創新企業 — NVTHK有限公司（「NVT」）20%股權。NVT為現實資產（「RWA」）代幣化市場的先行者。通過本次戰略性收購，公司已站在一個有望重塑全球資本市場，並於未來數年實現高速增長的行業前沿。NVT — 開創性市場先行者NVT是香港領先的RWA代幣化基礎設施提供商，通過其強大的OTC平台，構建了行業首個可支持頂級金融機構一級發行和受監管代幣化資產鏈上二級交易的完整生態系統。其高度整合的封閉式平台，連接資產發行人、投資者及流動性提供者，為金融業帶來前所未有的效率及流動性。NVT擁有享譽盛名的機構級客戶陣容，涵蓋頂尖金融機構、資產管理人及Web3創新企業，包括信達國際資管、廣發證券、金洲資產管理、Animoca Brands及HashKey Group。現時平台支援多類型金融產品的代幣化發行，如貨幣市場基金、結構性產品、債券及私募股權基金，展現其廣泛應用及市場認可度。此次收購對中聯發展控股的戰略意義根據波士頓諮詢集團（BCG）於2025年4月發布的報告，全球RWA代幣化市場預計將由2025年的0.6萬億美元在中位情景下增長至2033年的18.9萬億美元，年均復合增長率達53%。該行業的快速擴張反映了機構及零售投資者對高收益、透明且易於直接投資的資產類別的需求日益增加。透過收購NVT 20%股權，本公司將獲得：- 經驗豐富且全面合規的一站式機構級代幣化平台；- 獨家接入香港首個可在鏈上OTC市場進行二級交易的RWA生態系統；- 已建立的全球分銷網絡 — 迅速連接流動性提供者、資產發行人及投資者；- 與行業領袖夥伴攜手進一步建立市場公信力及拓展市場觸及範圍。本次收購大幅加速公司進軍高速增長的RWA市場，無需承擔從零自建平台所帶來的延誤、風險與資本開支。該收購亦符合本公司致力於探索創新與新業務機會，以實現收入多元化的承諾。戰略合作領域在此次投資完成後，公司與NVT將於兩大戰略範疇展開合作：皮革生產及供應鏈RWA代幣化依託NVT平台，本公司將率先於全球推動皮革行業實體及無形資產（包括現金流、應收帳款、存貨及知識產權等）的代幣化，實現營運資金釋放、開拓新投資渠道、自動化結算並拓展全球流動性。拓展新的RWA垂直領域雙方將共同開發並規模化推進其他行業的RWA解決方案，結合本公司產業專長與NVT經驗驗證的基礎設施，把握多元資產類別中的潛在機遇。中聯發展控股集團有限公司行政總裁趙靖飛表示：「本次投資NVT代表著公司跨越性發展的重要一步。NVT作為行業先行者及領導者，結合獨有鏈上一级及二級交易能力及卓越客戶基礎，令我們可深度參與萬億級增長機遇，加速核心業務數碼化並創造長遠股東價值。」NVT創辦人兼行政總裁趙建公表示：「我們的使命是運用區塊鏈技術重新定義資本市場，特別聚焦於亞洲金融中心 — 香港。通過與中聯發展的合作，我們將來自實體產業的優質資產引入並無縫對接至資本市場。此次合作不僅進一步強化了我們的平台實力，也為我們的合作夥伴生態系統創造了可觀的價值增長機遇，同時明確聚焦於為股東實現長期回報最大化。我們所構建的僅僅是一個開始 — 在未來，全新的商業模式、創新的資產類別以及可擴展的增長潛力將展現出無限可能。」關於NVTNVTHK有限公司（「NVT」）為總部位於香港的金融科技創新企業，專注現實資產（RWA）代幣化基礎設施、虛擬資產經紀系統及穩定幣技術方案。NVT 為香港首家通過 OTC 平台實現受監管代幣化資產鏈上交易的企業，為發行人、投資者及中介機構提供企業級技術解決方案。關於中聯發展控股集團有限公司中聯發展控股集團有限公司（「CIDC」）於開曼群島註冊成立，並於香港聯合交易所主板上市（股份代號：0264）。作為一家成熟的投資控股公司，CIDC 在高品質皮革製品的製造與分銷方面建立了堅實基礎。CIDC 積極推動創新與轉型戰略，尋求突破傳統核心業務的更多機遇。公司始終致力於尋找新業務與價值創造的契機，並適時擴展經營範疇與投資版圖。傳媒垂詢：NVTHK有限公司梁海燕 電話:2522 3869 電郵: Olivia.leung@newvisiongp.com網址: www.nvt.cim.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 大洋集團控股有限公司 (「大洋集團」或「集團」；股份代號：1991) 作為在港上市近廿載的老牌港股，擬進一步向Web4.0領域及染指人工智能（AI）產業全面進軍，將以AI數字人作為其後續成長引擎，結合真實世界資産（Real World Assets，RWA）代幣化運營平台，及其固有的全球流量營銷運營體系，針對教育、遊戲、大健康三大萬億賽道進行戰略佈局。在人工智能（AI）為全球數字化捲起新浪潮的大局下，AI正從「技術工具」躍升成為不少企業的「變革核心」，並驅使各行業改變工作方式、突破效率邊界、重塑其價值邏輯。IDC研究顯示，企業每投資1元在生成式AI身上，其投資回報率可達3.7倍；而深度擁抱AI的企業已實現平均13個月的價值回報周期，超過50%的組織正加速定制化AI應用開發，將短期收益轉化爲長期競爭優勢。普華永道預測，到2030年，AI將成爲全球經濟的規則改變者，貢獻高達 15.7 萬億美元的增長，為中國經濟帶來約26.1%的 GDP增量。無怪AI數字人作為不同行業多模式交互核心載體，已逐步從概念邁向產業落地。大洋集團於2023年投資的專業數位營銷服務公司巨省科技有限公司（「巨省科技」）擬推出其自主研發、技術融合機器學習、自然語言處理（NLP）、計算機視覺（CV）、語音合成／識別（TTS／STT）等領先技術、可兼容xAI Grok API的AI數字人，此AI數字人處於行業領先水平，並擬面向教育、遊戲及大健康的三大場景推出，形成包括但不限於，如能夠根據學生專注力實時調整語速及學習難度的「虛擬老師」AI數字人、藉因應每位玩家不同選擇互動而衍生「玩家專屬」的劇情之AI NPC、可根據個人7x24小時的健康數據如心率、血壓等主動建議的「健康伴侶」AI數字人等；集團計劃採取「分階段疊代、逐步開放」的策略，即預期將於未來6個月內完成核心模塊及底層技術整合，並目標於緊接的第6至18個月就上述三大場景發佈AI數字人原型，並接入巨省科技之營銷矩陣，期望於第18至36個月內能開放相關API或SDK接口，並吸引全球開發者構建其開放式生態圈。除此之外，集團更擬透過是次向AI與數字化轉型的契機，計劃透過區塊鏈RWA（Real World Assets，真實世界資產），將具備現金流的鏈下資產項目通過AI數字人實時抓取寫進智能合約當中，並將針對教育版權、遊戲IP在內等資產進行分層打包及發行，以配合不同投資者的風險偏好，集團目標此類資產發行，首年將對10個優質項目進行「試水式」發行，冀能於未來3年擴展至100個項目，涉及資產規模總值5億港元；力爭5年內服務的資產規模總值能突破50億港元，打造出多領域RWA資產運營平台。值得留意的是，RWA交易過程中，無需傳統經紀商或中間機構的參與，便可實現實體經濟與虛擬市場的結合。根據波士頓諮詢顧問公司的估計 =，至2030年，RWA代幣化市場的市值規模可能成長至16萬億美元。由此可見，其巨大的市場潛力以至前景。依託巨省科技20年跨境投放經驗，大洋集團將構建「全域覆蓋+智能運營+規模增長」流量體系。巨省科技服務之平台覆蓋TikTok、Instagram、Facebook等海外社交平台及抖音、微信視頻號等國內渠道，有助客戶實現全球用戶觸達；並可借助AI技術實現賬號養號、內容生成、定向投放全流程自動化，降低運營成本，提升獲客效率。以此推算，大洋集團對用戶增長目標明確：首年引流100萬用戶構建初始流量池，目標3年內超千萬，5年內打造億級Web4.0原生流量池，形成「流量－轉化－複購」的循環。大洋集團將藉上述規劃打造「數據化（Digitalization）－資産化（Assetization）－代幣化（Tokenization）（下稱‧DAT）」閉環，實現價值三層轉化：於數據化階段，將教育教案、遊戲脚本等多元數據標準化，打破數據孤島；在資産化階段，將用戶交互沉澱換算為可量化資産，比如教育「個性化教研數據包」可提升AI數字人老師課程之續費率、遊戲「劇情擴展資産」延長遊戲生命周期等；在代幣化階段，將可通過滴灌通DRO模型質檢之達標資産上鏈發行，全球投資者可7×24小時交易，放大流動性溢價。針對上述AI及數字化轉型戰略藍圖的投入規劃，大洋集團預期首年投入1.3億港元，目標未來5年內實現現金流正向循環。大洋集團主席施琦女士表示：「大洋發佈助力企業AI與數字化轉型藍圖，並正式進入數字資產領域，標誌着集團一項重要里程碑，亦為未來更多元化發展掀開嶄新的一頁。我們感謝各投資者對公司以發展的肯定及信心。大洋集團作為一間在港上市近廿載的老牌港股，透過是次涉足AI產業的舉措，未來有望衍生四種收入，包括AI數字人引流的收入、為中小企業提供 AI+RWA 一站式融資諮詢的收入、與RWA交易相關的撮合手續費以至數字投顧訂閱費、以及按項目或年費提供多語言、多文化 AI 客服與營銷外包收入，且巨省科技受惠其業態，近年持續保持正向現金流，亦為是次其向AI及數字轉型進一步拓展大計，提供充裕的自有資源，而隨着集團透過巨省科技走入AI領域的藍圖逐步變成現實，屆時可望為股東創造更多價值並帶來理想回報。」關於大洋集團控股有限公司(股份代號: 1991)大洋集團控股有限公司（股票代號：1991）成立於 1991 年，2007 年在香港聯合交易所有限公司成功上市，是一家兼具三十年産業積澱與前瞻數字視野的多元化企業。自創立以來，集團早期聚焦矽膠輸入設備領域，專業設計及製造用於消費電子裝置、計算機、筆記本電腦、手提電話及汽車周邊産品的核心部件，憑藉高度整合的生産體系、嚴苛的品質管控與技術創新能力，贏得全球眾多知名品牌客戶的長期信賴，奠定了堅實的産業根基。隨着全球數字化轉型浪潮的深化，大洋集團敏銳洞察數字經濟時代的戰略機遇，果斷啓動向 Web4.0 領域的全方位戰略轉型，以「擁抱技術變革、重構價值生態」為核心方向，精準錨定人工智能（AI）、真實世界資産（RWA）代幣化及香港政策生態三大核心驅動力，致力於打通 「數據 — 資産 — 價值」 的轉化鏈路，開啓從傳統製造向數字經濟領航者的跨越。當前，大洋集團正以 Web4.0 戰略轉型為新起點，聚焦教育、游戲、大健康三大萬億賽道，致力於成為亞太地區 AI 與 RWA 雙賽道的領先企業，為全球投資者、合作夥伴及個人用戶提供高效的價值增長生態，持續推動全球數字經濟高質量發展，寫下從「産業深耕者」到「數字生態構建者」的全新一頁。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025年中期業績亮點- 業務總收益同比增長9.40%至約新台幣585.31百萬元- 毛利同比增長28.98%至約新台幣201.97百萬元- 整體毛利率則上升5.24個百分點至約34.51%- 本公司擁有人應佔期間全面收益總額同比大幅增長118.02%約至新台幣68.24百萬元- 統包解決方案的收益約新台幣113.69百萬元- 每股基本盈利同比增長25.84%至約為新台幣4.87仙香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 靖洋集團控股有限公司（「 靖洋集團」或「集團」，股份代號：8257.HK）宣佈截至 2025年6月 30 日止六個月（「期內」）之中期業績。期內，集團業績呈現穩健增長態勢。集團總收益達約新台幣585.31百萬元，同比增長9.40%。毛利同比增長28.98%，達約新台幣201.97百萬元，而整體毛利率則上升5.24個百分點至約34.51%。本公司擁有人應佔期間全面收益總額約新台幣68.24百萬元，同比大幅增長118.02%。每股基本盈利約為新台幣4.87 仙，同比增長25.84%。期內，統包解決方案的收益約新台幣113.69百萬元，佔集團總收益約19.42%。零件及二手半導體製造設備買賣的收益約新台幣471.62百萬元，零件及買賣二手半導體製造設備佔集團總收益約80.58%。本集團秉持著審慎、穩健的核心策略，致力強化與現有國際客戶合作的穩定性和持續性，同時積極拓展新客戶以分散風險。期內，本集團源自美國業務的收入較去年大幅增加78.54%，佔集團總收益約38.68%，而源自台灣業務的收入則較去年增加48.97%，佔集團總收益約49.69%。2025 年上半年，全球半導體市場延續增長態勢。在AI 等新技術的驅動下，汽車電子、新能源、物聯網、大數據和人工智能等領域的新技術、新產品滲透率持續提升。此外，「人工智能+」、「5G+」等前沿技術的深化發展，以及AI 算力需求的快速增長，均成為推動半導體需求的重要動力，為半導體企業營造了良好的發展環境。根據半導體產業協會最新報告，2025年5月全球半導體銷售額達590億美元，較2024年5月的492億美元增長19.8%，連續19個月實現同比增長；環比則增長3.5%。全球晶片市場的增長主要受美洲和亞太地區強勁需求推動。靖洋集團主席兼行政總裁楊名翔先生總結：「在AI 技術的強勁驅動下，半導體行業迎來經濟利潤快速增長期。然而，當前國際形勢波動，其亦面臨供應鏈穩定性的挑戰。本集團將審時度勢，穩中求進，持續提升核心價值與競爭力，為股東創造可持續的長期投資回報。」 關於靖洋集團控股有限公司（股份代號：8257.HK）靖洋集團控股有限公司為一間總部位於台灣的零件及二手半導體製造設備的統包解決方案供應商及出口商。集團自於2009年開始業務以來，主要為客戶提供零件二手半導體製造設備件的統包解決方案，按客戶需要改造及/或升級其生產系統的半導體設備，亦從事半導體製造設備及其零件買賣。集團所提供的半導體製造設備及零件包括熱爐管、顯影裝置等，用於半導體的前端製造過程、晶圓加工，如沉積、光阻塗佈及顯影，更可廣泛應用於手機、遊戲機、DVD播放機，以及車用感應器等數碼電子產品。本新聞稿由滙滔顧問有限公司代表靖洋集團控股有限公司發佈。詳情垂詢：劉育然小姐電話：(852) 2529 7999電郵：Natural.lau@vitalink.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 聚焦於腫瘤治療領域的創新型生物製藥公司--樂普生物科技股份有限公司(「樂普生物」或「公司」，股份代號：2157.HK)公佈2025年中期業績。報告期內，公司業務呈現強勁增長態勢，首次實現盈利，核心產品銷售與國際授權業務齊頭並進，ADC管線多產品進入關鍵臨床階段，全球商業化佈局加速推進。作為一家立足中國、面向全球的聚焦於腫瘤治療領域（尤其是靶向治療及免疫治療）的創新型生物製藥企業。樂普生物致力於通過全面且先進的ADC技術開發平台開發創新型ADC，並旨在開發出優化、創新的藥物，更好地填補癌症患者的臨床需求缺口。公司致力於通過充分整合自主創新能力及戰略合作，持續開發市場差異化產品管線。隨着ADC候選藥物即將進入商業化階段，公司已建立並正在逐步擴大內部生產能力以滿足業務發展的需求。目前，樂普生物已戰略性佈局了多個腫瘤產品管線。就臨床階段候選藥物而言，公司的產品中有一種臨床/商業化階段候選藥物、九種臨床階段候選藥物（包括一種透過合營企業共同開發的藥物）、三種臨床階段的候選藥物的聯合療法。其中一種候選藥物已獲得兩種靶向適應症的上市批准，其他適應症臨床試驗正在進行中。在九種臨床階段候選藥物中，七種靶向療法藥物，兩種免疫治療藥物（屬於一種溶瘤病毒藥物及T細胞激動性抗體）。截至報告期末，通過商業化及業務開發活動，樂普生物在研發能力變現方面取得重要里程碑：普佑恆(R)（普特利單抗注射液）已完成商業化全流程，目前正處於銷售快速增長階段，另有4款產品CMG901、MRG007以及两项临床前TCE资产也通過業務開發活動成功達成授權合作。CMG901的全球權益已授權給AstraZeneca，MRG007的大中華區以外權益已授權給ArriVent，两项临床前TCE资产与Excalipoint达成合作。收入規模實現3.5倍跨越式增長 財務指標全面改善2025年上半年，公司在推進產品管線及業務營運方面均取得重大進展，錄得總收入約人民幣4.66億元，較2024年同期的人民幣1.33億元增長350%。就許可業務而言錄得收入約人民幣3.09億元，主要來自MRG007的對外授權許可；錄得銷售普佑恆(R)（普特利單抗注射液）的收入約人民幣1.51億元，較2024年同期大幅增加58.8%。此外，就提供CDMO服務錄得收入約人民幣630萬元。於報告期內，公司首次實現盈利，期內利潤約人民幣2930萬元，較2024年同期實現扭虧為盈；經營活動產生的現金淨額約人民幣4670萬元，現金及現金等價物增至約人民幣4.73億元，較2024年同期實現經營現金流量淨額轉正；研發開支約人民幣2.02億元，較2024年同期下降6.6%，在保障核心管線推進的同時，成本控制成效顯現。公司積極發展與各種業務渠道合作夥伴的合作關係。截至2025年6月30日，公司已在中國28個省份的採購平台上完成了招標程序，已通過各種銷售渠道覆蓋中國約118個城市，將進一步擴大銷售網絡。ADC管線多產品進入關鍵階段 聯合療法潛力凸顯 國際授權成果豐碩於2025年上半年，公司繼續專注於其候選藥物的研發，同時不斷評估與腫瘤治療範圍及候選藥物涵蓋的廣泛適應症相關的市場需求和競爭格局，以最大化提高其產品管線的競爭力。其中，MRG003用於治療NPC適應症即將獲批，其他核心候選藥物進入關鍵註冊性臨床階段。MRG003（EGFR-ADC）：NPC：MRG003關於治療R/M NPC適應症正在接受NDA審評，且亦已獲國家藥監局CDE授予的優先審評。監管機構目前正進行MRG003的臨床及藥學審核。用於治療R/M NPC的IIb期關鍵臨床研究的良好數據於2025年ASCO大會上作為「重磅研究摘要」(LBA)讀出，且以口頭匯報形式呈現。目前公司亦正在進行MRG003與普特利單抗聯合治療R/M NPC的III期臨床試驗。該聯合療法的II期臨床試驗的良好數據將於2025年ESMO大會上呈現。HNSCC：截至2025年6月30日，公司正在進行HNSCC的隨機、開放、多中心III期臨床研究。對於MRG003與普特利單抗的聯合治療，目前正在進行HNSCC的II期臨床試驗，且II期臨床試驗的良好數據將於2025年ESMO大會上呈現。2025年6月，該聯合療法用於治療LA-SCCHN的II期臨床試驗的臨床試驗申請(CTA)獲歐洲藥品管理局(EMA)批准，公司將於2025年下半年開展該臨床試驗。MRG004A（TF-ADC）：公司已在中國完成實體瘤I期臨床研究，且PC適應症的Ib期良好數據將於2025年ESMO大會上呈現。就MRG004A的關鍵註冊性臨床試驗方案與CDE的溝通已完成，並已於2025年8月進入III期臨床試驗階段。此外，MRG004A於2025年8月獲CDE授予BTD，為胰腺癌患者提供全新的治療選擇。MRG006A（GPC3-ADC）：MRG006A是一款具有全球FIC潛力的GPC3靶向ADC產品，於2025年1月獲得FDA的IND批准，目前正在中國推進I期臨床試驗。於臨床前研究中，MRG006A在多種CDX模型及HCC PDX模型中展現出強大的劑量依賴性的對腫瘤的生長抑制作用。同時，MRG006A亦在探索性毒理學研究中表現出良好的耐受性。MRG007（CDH17-ADC）：2025年6月獲國家藥監局IND批准，目前正在開展治療不可切除的局部晚期或轉移性實體瘤的Ia期臨床試驗。其在消化道癌的臨床前模型中表現出強大的抗腫瘤活性，並在IND支持性研究中顯示出良好的治療指數。MRG007的臨床前數據已於2025年4月的AACR年會上呈報。2025年1月，公司與ArriVent訂立獨家許可協議，授予ArriVent在大中華區以外地區開發、製造和商業化MRG007的全球獨家許可。根據協議條款，公司有資格獲得總計最高達12億美元的首付款及開發、註冊及銷售里程碑付款，連同銷售淨額的分級特許權使用費。截至2025年6月30日，已收到該筆首付款。CG0070（溶瘤病毒）：CG0070於2025年1月獲CDE授予BTD。目前公司的美國合作夥伴CG Oncology正在針對CG0070進行MRCT III期臨床研究。觀察到的最新良好數據已在2025年4月第120屆美國泌尿外科協會年會上以口頭匯報形式呈現。公司已完成在中國的I期臨床試驗，目前正與CDE就國內關鍵橋接臨床試驗進行方案溝通。聯合療法布局：截至2025年6月30日，公司已完成MRG002與普特利單抗聯合治療HER2表達實體瘤的II期試驗（該試驗已提線至一線治療），且III期臨床試驗的方案溝通已完成。公司已於治療UC中觀察到良好的數據；在MRG003與普特利單抗聯合治療方面，公司目前正在進行HNSCC的II期臨床試驗（該試驗已提線至一線治療），而良好的II期臨床試驗數據將於2025年ESMO大會上公佈。2025年6月，該聯合療法用於治療LA-SCCHN的II期臨床試驗的臨床試驗申請(CTA)獲歐洲藥品管理局(EMA)批准，將於2025年下半年啟動臨床試驗（該試驗已提線至一線治療之前局晚期）。臨床前：佈局創新平台和創新靶點公司持續致力於建立和開發新型技術平台，將其作為本公司的創新引擎。公司亦已為ADC候選藥物開發多個創新的鏈接體－有效載荷平台，包括Hi-TOPi ADC平台及其他早期階段的平台。於報告期內，公司的創新ADC平台取得了重大進展。依託該等創新平台，公司已開發出兩款ADC候選藥物，分別為具有全球首創新藥潛力的MRG006A及具有全球同類最優潛力的MRG007，均已顯示良好的臨床前數據，並於中國獲得了IND批准。MRG007的臨床前數據已於2025年4月在AACR年會上呈現。於2025年8月1日，本公司已與Excalipoint訂立知識產權轉讓及許可協議，就對外授權及/或轉讓與公司專有的T細胞銜接器平台TOPAbody開發的兩項臨床前資產有關的若干知識產權訂立許可交易。公司將收取總額為1000萬美元的現金首付款、總額最高為8.475億美元的研發及商業里程碑付款及銷售特許權使用費，並持有其10%股權，標誌着平台價值獲得國際認可。未來展望：加速核心產品商業化 推進全球戰略布局在藥物研發方面，公司將進一步聚焦於推動下一代ADC藥物及免疫腫瘤雙╱三特異性抗體的戰略研發，同時加快後期產品的商業化。對於註冊階段產品MRG003，有關監管機構目前正有序進行臨床及藥學審核，公司將集中資源，全力加速其獲批進程。同時，其他核心候選藥物進入臨床關鍵階段。MRG004A關鍵性臨床試驗方案溝通已完成，且已於2025年8月進入III期臨床試驗階段。此外，目前正與CDE就CG0070的國內關鍵臨床試驗進行方案溝通。公司亦將探索MRG006A及MRG007等其他創新候選藥物的更多潛在臨床價值。同時，公司正在不斷探索管線內聯合療法的潛在療效，努力為更廣泛的患者群體帶來更大的臨床效益。在國內商業化方面，公司將採取進一步措施提高普佑恆(R)（普特利單抗注射液）的市場可及性，加快各級市場滲透，進一步擴大市場份額；提升公司的品牌形象及市場認知度。同時，公司將開始籌備MRG003的商業化上市，並繼續擴大營銷及商業化團隊。在國際方面，公司將加大在全球市場的拓展力度，擴大國際網絡，並探索新的業務開發合作機會。公司將繼續致力於在全球範圍內尋找更多戰略合作夥伴，通過合作、授權協議或合資企業等方式開發公司的ADC產品和其他創新候選藥物。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025. During the reporting period, the Company's business showed strong growth momentum, achieving profitability for the first time. Core product sales and international licensing business progressed in tandem, with multiple ADC pipeline products entering key clinical stages and global commercialization efforts accelerating.Lepu Biopharma is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. Lepu Biopharma is dedicated to developing innovative ADCs through our comprehensive and advanced ADC technology development platform and we aim to develop optimal and innovative drugs to better serve the unmet medical needs of cancer patients. The Company is committed to continuously developing a market-differentiating pipeline by fully integrating independent innovation capabilities and strategic collaborations. The Company has established and is progressively expanding our internal manufacturing capabilities, driven by the business needs stemming from the upcoming commercialization of our ADC candidates.Currently, Lepu Biopharma has strategically designed our pipeline with a range of oncology products. For clinical-stage candidates, the Company has one clinical/commercialization-stage drug candidate; nine clinical-stage drug candidates, including one co-developed through a joint venture; and three clinical-stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the nine clinical-stage drug candidates, seven are targeted therapeutics and two are immunotherapeutics, which are an oncolytic virus drug and T cell agonistic antibody.As of the end of the reporting period, Lepu Biopharma has achieved significant milestones in the monetisation of our R&D capabilities through commercialization and BD activities: PUYOUHENG (Pucotenlimab Injection) has completed the full commercialization process and is currently under a rapid sales growth, and four other products, CMG901, MRG007 and two pre-clinical TCE assets have also been licensed out through our BD activities. Notably, CMG901’s global rights have been licensed to AstraZeneca, and MRG007’s rights for regions outside Greater China have been licensed to ArriVent. Two pre-clinical TCE assets have entered into a collaboration with Excalipoint.Revenue scale achieved a 3.5-fold leapfrog growth, with comprehensive improvement in financial indicatorsIn the first half of 2025, the Company made significant progress in advancing its product pipeline and business operations, recording a total revenue of approximately RMB466 million, which was an increase of 350% of the same period in 2024 at RMB133 million. For licensing activities, the Company has recognized approximately RMB309 million in revenue primarily from the out-licensing of MRG007. The Company recorded a revenue of approximately RMB151 million for the sales of PUYOUHENG (Pucotenlimab Injection), marking a significant increase of 58.8% from the sales recorded in the same period in 2024. In addition, the Group recognized approximately RMB6.3 million in revenue for the provision of CDMO services.During the reporting period, the Company achieved profitability for the first time, with a profit of approximately RMB 29.3 million, marking a turnaround from a loss in the same period of 2024. Net cash generated from operating activities was approximately RMB 46.7 million, and cash and cash equivalents increased to approximately RMB 473 million, representing a positive net operating cash flow compared to the same period in 2024. Research and development expenses amounted to approximately RMB 202 million, representing a decrease of 6.6% compared to the same period in 2024. While ensuring the advancement of core pipelines, cost control measures have shown tangible results.The Company actively develops cooperative relationships with various business channel partners. As of June 30, 2025, the Company completed the tendering process on the procurement platform in 28 provinces of the PRC. We have covered approximately 118 cities in the PRC through various sales channels, and we will further expand our sales network.ADC pipeline enters the critical phase with multiple products, potential for combination therapy highlighted, and fruitful international licensing resultsIn the first half of 2025, the Company remained focused on the research and development of its drug candidates, while continuously assessing market demand and competitive landscape relating to the range of oncology therapeutics and the broad spectrum of indications covered by its drug candidates, in order to maximize the competitiveness of its products pipeline. In particular, MRG003 for NPC nears approval and other key drug candidates advance to pivotal clinical stage.MRG003（EGFR-ADCNPC: MRG003 is under NDA review for the treatment of R/M NPC and has also been granted priority review by the CDE of NMPA. The authority is currently proceeding with the clinical and pharmaceutical evaluation of MRG003. The encouraging data of the pivotal Phase IIb clinical study for the treatment of R/M NPC was read out as “late breaking abstract (LBA)” for oral presentation at the ASCO Congress 2025. The Company is also currently conducting the Phase III clinical trial of combination therapy with MRG003 and pucotenlimab on R/M NPC. The encouraging data in phase II clinical trial of combination therapy on R/M NPC will be presented at the ESMO Congress 2025.HNSCC: As of June 30, 2025, the Company is conducting a randomized, open-label, multicenter Phase III clinical study on HNSCC. In terms of combination therapy with MRG003 and pucotenlimab, we are currently conducting the Phase II clinical trial on HNSCC, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and the Company will initiate the clinical trial in the second half of 2025.MRG004A (TF-ADC): The Company has completed the Phase I clinical study on solid tumors in China and the encouraging Phase Ib expansion data on PC will be presented at the ESMO Congress 2025. Protocol communication with CDE for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, MRG004A was granted BTD by the CDE in August 2025, which offers a brand-new treatment option to patients with pancreatic cancer.MRG006A (GPC3-ADC): MRG006A is a GPC3-targeted ADC with FIC potential globally. We received IND clearance from the FDA in January 2025. We are currently advancing Phase I clinical trial in China. In pre-clinical studies, MRG006A resulted in a robust and dose-dependent tumor growth inhibition on multiple CDX models and HCC PDX models. In the meantime, MRG006A also demonstrated good tolerability in the exploratory toxicology study.MRG007 (CDH17-ADC): We received the IND approval from the NMPA in June 2025 and are currently conducting a Phase Ia clinical trial for the treatment of unresectable locally advanced or metastatic solid tumors. MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025. In January 2025, the Company entered into an exclusive licensing agreement with ArriVent, pursuant to which the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China. Under the terms of the agreement, the Company is eligible to receive up to US$1.2 billion in total in upfront payment and development, regulatory and sales milestones, together with tiered royalties on net sales. As of June 30, 2025, the upfront payment has been received.CG0070 (Oncolytic virus): CG0070 was granted BTD by the CDE in January 2025. CG0070 is currently in a MRCT Phase III clinical study conducted by the Company’s U.S. partner, CG Oncology. The latest encouraging data observed has been orally presented in the 120th American Urological Association Annual Meeting in April 2025. The Company has completed the Phase I clinical trial in China and are currently engaged in protocol communication with the CDE regarding the domestic bridging pivotal linical trial.Combination therapy layout: As of June 30, 2025, the Company has completed the Phase II trial of combination therapy with MRG002 and pucotenlimab in the treatment of HER2-expressing solid tumors, which has moved to first-line treatment, and protocol communication for phase III clinical trial has been completed. The Company has observed encouraging data on UC. In terms of combination therapy with MRG003 and pucotenlimab, the Company is currently conducting the Phase II clinical trial on HNSCC, which has moved to first-line treatment, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and we will initiate the clinical trial in the second half of 2025, which has been moved up to first-line treatment for advanced disease.Preclinical: Laying the groundwork for innovative platforms and innovative targetsThe Company continuously strives to build up and develop novel technology platforms as innovative engines for the Company. The Company has developed multiple innovative linker-payload platforms for ADC drug candidates, including the Hi-TOPi ADC platform and other early-stage platforms. During the reporting period, our innovative ADC platforms have achieved significant progress. Based on these innovation platforms, the Company has generated two ADC candidates, which are MRG006A with global first-in-class potential and MRG007 with global best-in-class potential, all of which have shown encouraging pre-clinical data and received IND approvals in China. Pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.On August 1, 2025, the Company entered into a licensing transaction for the license-out and/or transfer of certain intellectual property rights relating to two preclinical assets developed by the Company’s proprietary T cell engager-TOPAbody platform with Excalipoint through entering into the Intellectual Property Assignment and License Agreement.The Company shall receive (i) an upfront payment in cash of US$10 million in aggregate, development and commercial milestone payments in cash of up to US$847.5 million in aggregate and sales royalties, holding a 10% interest, marking international recognition of the platform's value.Future Outlook: Accelerating the Commercialization of Core Products and Advancing Global Strategic DevelopmentIn respect of drug R&D, the Company will further focus on advancing strategic research and development priorities in next generation ADC drugs and IO bi/tri specific antibodies, while accelerating the commercialization of late-stage products. For our registrational stage product MRG003, the relevant authority is currently proceeding with the clinical and pharmaceutical evaluation in an orderly manner. The Company will concentrate our resources and endeavour to expedite the approval process. Meanwhile, our other key drug candidates are entering pivotal clinical stages. Protocol communication for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, we are currently conducting protocol communication with the CDE regarding the domestic pivotal clinical trial of CG0070. The Company will also explore further potential clinical value of our other innovative drug candidates, such as MRG006A and MRG007. Concurrently, the potential efficacy of combination therapies within our pipeline is being continuously explored, with greater clinical benefits striving to be delivered to a broader patient population.In terms of domestic commercialization, the Company will take further actions to enhance the market accessibility of PUYOUHENG (Pucotenlimab Injection), accelerating market penetration at all levels to further increase market share and enhance the Company's brand image and market recognition. At the same time, the Company will commence the preparation process for the commercial launch of MRG003 and continue to expand our marketing and commercialization teams.On the international front, the Company will ramp up our efforts to expand into the global market. We will expand our international network and explore new business development cooperation opportunities. The Company will remain committed to seeking more strategic partners worldwide to develop our ADC products and other innovative candidates through partnerships, licensing agreements, or joint ventures. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 「沒想到我的信用卡積分能夠為鄉村學童提供香噴噴的飯菜，這真是件特別幸福的事。」興業銀行一位信用卡客戶笑意燦然地對記者說道。近日，中國社會福利基金會對興業銀行頒發了《致謝證書》，用以表彰興業銀行多年來為「免費午餐公益項目」所做出的金融貢獻。早在2018年，興業銀行就與中國社會福利基金會攜手打造「免費午餐」信用卡積分捐贈項目——凡興業銀行信用卡持卡人均可通過興業銀行官微或手機銀行參與該活動，將自己日常生活中的信用卡消費積分投入「免費午餐基金」，為邊遠鄉村學童提供新鮮的雞蛋、翠綠的蔬菜、鮮美的紅燒肉和噴香的米飯。迄今為止，已有超過28萬名興業銀行信用卡持卡人參與其中，為鄉村學童提供了200萬份免費午餐。目前，興業銀行信用卡持卡人累計捐贈的善款在中國社會福利基金會「免費午餐基金」企業合作項目中位居前列。「我們很榮幸能夠通過金融力量築起這座愛心橋樑，也非常感謝廣大客戶對我們的信任與支持，讓這個公益項目發芽吐蕾、茁壯成長。」興業銀行信用卡中心負責人告訴記者。翻看受捐學校的官方微博，上面記錄著採購清單上跳躍的數字、大鍋裡翻滾的菜肴和孩子們雙手捧著餐盤時純真滿足的笑靨。持卡人的一筆筆捐贈、一次次善舉正在守護著鄉村學童的健康。「興業銀行信用卡積分捐贈的公益實踐，讓金融的溫度遇見公益的初心，為金融行業積極參與公益事業提供了有益借鑒。」中國社會福利基金會理事長詹成付表示。讓免費午餐成為中國兒童的基本福利——這是「免費午餐基金」的願景，需要社會各方力量的共同參與。興業銀行將與中國社會福利基金會進一步深化合作，搭建更多愛心橋樑，為已開展七年的「免費午餐」信用卡積分捐贈項目持續注入新動能。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 比優集團控股有限公司（「比優集團」或「本公司」，連同其附屬公司統稱「本集團」，股份代號：09893.HK）欣然宣布，近日集團獲國內領先金融數據平臺Wind提升ESG評級，由BB級躍升至A級，躋身行業前列，充分體現集團在可持續發展方面的卓越表現。Wind ESG評級A級代表企業在環境、社會及管治維度的綜合實力處於行業頭部領先水平。據Wind最新評級結果顯示，在基礎化工行業中，獲得A級的企業僅佔約19.35%，顯示出比優集團在ESG管理及實踐方面已居於行業上游。本集團ESG評級實現從BB至A的兩級跨越，主要得益於系統性的可持續發展舉措。根據比優集團最新發布的《2024/2025年度環境、社會及管治報告》，集團在環境層面全面落實大氣污染物减排、溫室氣體管控、廢弃物資源化及生態修復等項目，大力推進綠色礦山建設與社會責任履行；在社會維度，持續完善安全生産體系與員工健康保障，强化産品質量與供應鏈合規管理，特別是在「一帶一路」沿綫國家推行本地化運營，積極踐行社區共建與企業公民責任；在管治維度，集團建立了系統、全面的合規管理制度和風險控制流程，通過常態化的審計監察與員工培訓，嚴守商業道德底綫，積極預防舞弊與腐敗行爲，幷設立了對董事會直接負責的ESG工作組，將可持續發展深度融入公司治理核心。Wind作爲中國金融信息服務業最具權威性與影響力的平臺之一，其ESG評級體系依托强大的數據治理能力與深厚的行業積累，構建了涵蓋大量定量與定性指標的科學評估框架。該體系接軌國際標準，深度融合中國本土信息披露政策與企業實踐，Wind ESG評級結果與底層數據已全面覆蓋A股、港股上市公司，公募信用債發債主體及國內公募基金。本次比優集團ESG評級的上調，反映了其在治理結構優化、環境與社會績效提升、以及信息披露質量方面獲得第三方評級機構的高度認可。董事會相信，此次評級的躍升不僅體現了集團在可持續發展方面的扎實進展，也將進一步强化投資者的信心。未來，比優集團將繼續深化綠色運營、推進技術革新，持續提升ESG管理的透明度，積極踐行可持續發展理念，推動實現高質量的企業成長。關於比優集團控股有限公司比優集團控股有限公司（主板股票代號：09893.HK）是一家專注於民用爆炸品的生産銷售、爆破工程服務，礦山資源開發和勘探業務的領軍企業。集團在國內市場佔據重要份額，幷在中亞等全球市場積極拓展業務。公司網址：http://www.pizugroup.com Copyright 2025 亞太商訊 via SeaPRwire.com.

SHENZHEN, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Following its highly anticipated global reveal earlier this month, Level Infinite will launch the game's 1st Closed Beta in early November. Players can be the first to get a hands-on with the game this week at gamescom 2025 in Cologne from 20th to 24th August. Rust Mobile delivers a full-scale open-world survival gameplay that millions of fans know and love, optimized for mobile devices.Officially licensed by Facepunch Studios, Rust Mobile stays true to the spirit of the original while introducing a fresh way to survive on the go. From gathering resources and building fortified bases to ruthless PvP combat and the tension of trust and betrayal, the mobile version captures the essence of Rust. Players will have the opportunity to experience all the excitement the game offers firsthand at both gamescom and through the upcoming Closed Beta Test.Rust Mobile at Gamescom 2025Attendees can find the Rust Mobile booth in Hall 06.1 - C-051G, where they'll get hands-on time with the game and take part in activities designed to bring the world of Rust to life. Activities include interacting with themed props, immersing themselves in the booth environment.Every participant will also earn a spin on the Loot Wheel, with the chance to win exclusive Gamescom 2025 memorabilia, including limited-edition posters and tote bags.1st Closed Beta Coming This NovemberRust Mobile's 1st Closed Beta will launch in early November 2025, inviting 30,000 players from North America, Western Europe, and select regions in Asia.The beta will feature four language options English, Japanese, Traditional Chinese, and Thai and will support iOS, Android, and tablet devices, ensuring players can experience the game on their platform of choice.Registration for the Closed Beta Test is now open at www.rustmobile.comFor more information about Rust Mobile or to pre-register, head to rustmobile.com, or follow the game on X, and YouTube. For gamescom opening times visit www.gamescom.global.About Level InfiniteLevel Infinite is Tencent's global games brand, dedicated to delivering engaging and original gaming experiences to a worldwide audience, whenever and wherever they choose to play. The brand also provides a wide range of services and resources to a network of developers and partner studios around the world to help them unlock the potential of their games. Level Infinite is both publisher of breakout hit games like PUBG MOBILE, Honor of Kings and Goddess of Victory: NIKKE and a collaborative partner in games such as Dune: Awakening from Funcom, Warhammer 40K: Darktide and many more. To learn more about Level Infinite, visit www.levelinfinite.comContact InformationKirsty EndfieldSwipe Right PRtencent@swiperight.ggSOURCE: Level Infinite Copyright 2025 ACN Newswire via SeaPRwire.com.

FINANCIAL HIGHLIGHTS RMB’000 (Unaudited)Six Months Ended June 30Three Months Ended June 302025202420252024 Revenue4,645,407 4,610,641 2,307,412 2,473,766 - Office software and services2,657,122 2,413,079 1,355,653 1,187,730 - Online games and others1,988,285 2,197,562 951,759 1,286,036 Gross Profit3,772,214 3,782,688 1,853,628 2,042,035 Operating Profit984,111 1,395,615 382,658 794,037 Profit Attributable to Owners of the Parent816,314 677,923 532,440 393,353 Basic Earnings Per Share (RMB)0.60 0.51 0.39 0.29 HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Kingsoft Corporation Limited (“Kingsoft” or the “Company”; HKEx stock code: 03888), a leading Chinese software and Internet service company, has announced its unaudited 2025 interim results and its second quarter results for the period ended 30 June 2025.For the first half of 2025, the revenue of Kingsoft increased by 1% year-on-year to RMB 4,645.4 million. Revenue from the office software and services represented 57% and online games and others represented 43% of total revenue. Gross profit reached RMB 3,772.2 million.For the second quarter of 2025, the Company’s revenue reached RMB 2,307.4 million. Revenue from office software and services and online games and others represented 59% and 41%, respectively, of total revenue for the second quarter of 2025. Gross profit for the second quarter of 2025 was RMB 1,853.6 million.Mr. Jun LEI, Chairman of the Company, commented: “In the second quarter, we advanced core businesses steadily in line with established strategy and firmly positioned for the future. Kingsoft Office focused on ‘AI, collaboration, and internationalization’, continued to strengthen the allocation of R&D resources in related fields, and developed solutions deeply aligned with user scenario needs to sustain competitiveness in the field of intelligent office. The online games business continued advancing content innovation and global expansion, achieving the development of flagship IPs and new game genres.”Mr. Tao ZOU, Chief Executive Officer of the Company, added: “The total revenue for the second quarter amounted to RMB 2,307.4 million, representing a year-on-year decrease of 7%, among which the revenue from the office software and services business was RMB 1,355.7 million, representing a year-on-year increase of 14%. Revenue from the online games and others business was RMB 951.8 million, representing a year-on-year decrease of 26%, primarily due to the high base in the same period last year.”BUSINESS REVIEWOffice Software and ServicesFor the first half of 2025, revenue from the office software and services business increased by 10% year-on-year to RMB 2,657.1 million. The increase was mainly attributable to the growth of WPS individual and WPS 365 businesses of Kingsoft Office. Revenue in the second quarter increased by14% year-on-year to RMB 1,355.7 million.In the second quarter, the office software and services business continued its healthy development. For WPS AI, Kingsoft Office released WPS AI 3.0 and launched the native Office intelligent agent ‘WPS Lingxi’ — the core capability module of WPS AI 3.0. WPS AI 3.0 drove deep integration between AI and office software through bidirectional transformation, achieving native embedding of AI capabilities and deep involvement in office workflows. WPS Lingxi integrated multiple AI functions, marking the transition from tool-based AI applications to collaborative intelligent agents. We also implemented intelligent upgrades to WPS 365 components, and launched messaging, meeting, and email assistants to boost office efficiency.For WPS individual business, Kingsoft Office expanded AI benefits and rolled out new AI products. In overseas markets, we initiated the development of the new WPS International Edition to gradually migrate domestic high-value features. For WPS 365 business, we continuously deepened penetration into industries and scenarios, actively promoted the implementation of AI projects, and engaged in co-creation with key clients to replicate and scale up typical solutions. For WPS software business, we actively participated in the bidding for domestic office software of central and local governments and enterprises. Our products maintained a leading share in both flow layout and fixed layout document software market.Online Games and othersFor the first half of 2025, revenue from online games and others business reached RMB 1,988.3 million, and revenue for the second quarter of 2025 was RMB 951.8 million. In the second quarter, the online games business continued to enrich the brand value of classic JX series and expand into new game genres.During the second quarter, JX3 Online, the flagship IP, maintained engaged player base through consistent content updates and technical optimization. The Fate of Sword: Zero was launched, building upon the core gameplay of the classic JX series IP while introducing innovative explorations. The anime shooter game Snowbreak: Containment Zone sustained its long-term operation, keeping stable user base. The self-developed sci-fi mech game Mecha BREAK commenced its global public beta in July. On its launch day, it topped Steam’s lists for both “Most Played” and “Trending Games,” and earned high scores from several international authoritative gaming outlets like IGN.Additionally, we actively strengthened our collaboration with high-quality overseas IPs, deepening the localized operational capabilities in domestic market. The social deduction game Goose Goose Duck obtained the license approval in June and was expected to launch in the second half of the year. The number of pre-registrations exceeded 5 million, demonstrating its popularity. Cats & Soup: Magic Recipe, the sequel to Cats & Soup, secured its license in May. For the latter half of the year, we will focus on refining the operations of our core titles and continuously optimizing the gaming experience based on players’ feedback.Mr. Jun LEI concluded, “In the coming quarters, Kingsoft Office will continue to increase its R&D investments in AI and collaboration, and promote the implementation of its products and services across a wider range of office scenarios in various industries. The online games business will remain focused on premium games, continue to cultivate its IP franchise, steadily advance its global expansion and achieve long-term operations. We believe that these efforts will strengthen the Group’s core competitiveness and lay a solid foundation to achieve long-term high-quality growth.”About Kingsoft Corporation LimitedKingsoft (3888.HK) is a leading Chinese software and internet service company listed on the Hong Kong Stock Exchange. It has three main subsidiaries: Kingsoft Office, Seasun Holdings and Kingsoft Shiyou. With the implementation of the “transformation toward mobile internet” strategy, Kingsoft has completed a comprehensive transformation in its overall business and management model. The Company has established a strategic layout with office software and interactive entertainment as its pillars, and cloud services and artificial intelligence as its new starting points. Kingsoft has more than 8,000 employees worldwide and holds a significant market share domestically. For more details, please refer to http://www.kingsoft.com.Kingsoft Investor Relations:Li Yinan Tel: (86) 10 6292 7777Email: ir@kingsoft.comFor further queries, please contact Hill and Knowlton:Ovina Zhu Tel: (852) 2894 6315Email: kingsofthk@hkstrategies.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - To promote Hong Kong’s business advantages and enhance trade and economic cooperation between Hong Kong and Thailand and the wider ASEAN region, Prof Frederick Ma, Chairman of the Hong Kong Trade Development Council (HKTDC), visited Bangkok and met with senior government and business leaders.Prof Ma spoke on a panel at the Singapore Regional Business Forum organised by the Singapore Business Federation. He said, “Businesses are diversifying amid the changing landscape. Asia remains a major engine for economic growth, underpinned by the rise of emerging markets, like ASEAN and the Middle East. China, with its industrial base and vast population, is a stabilising force in an ever-changing world. And Hong Kong, given its superconnector and super value-adder roles, is a dynamic platform linking Mainland China with the world.”Aside from the event, Prof Ma met with Chantawit Tantasith, Deputy Minister of Commerce of Thailand, and Dhanin Chearavanont, Senior Chairman of Charoen Pokphand Group, to exchange views on deepening Hong Kong-Thailand trade and economic cooperation.Prof Ma noted: “Thailand is an important trade and investment partner for Hong Kong. I am delighted that I had the opportunity to exchange insights with the Ministry of Commerce and leading enterprises in Thailand as well as political and business leaders from Singapore to further strengthen the economic ties between Hong Kong and Thailand and the wider ASEAN region.”As a statutory body, the HKTDC promotes, assists and develops Hong Kong’s external trade, while supporting Hong Kong businesses to tap into the opportunities in ASEAN. The HKTDC’s flagship events, such as the Asian Financial Forum and the Belt and Road Summit, serve as ideal platforms to highlight the latest developments and opportunities in Hong Kong as well as the city’s advantages in professional services, while facilitating cross-regional collaboration. Photo Download: http://bit.ly/4lBDJFAHKTDC Chairman Prof Frederick Ma meets with Chantawit Tantasith, Deputy Minister of Commerce of ThailandHKTDC Chairman Prof Frederick Ma meets with Dhanin Chearavanont, Senior Chairman of Charoen Pokphand GroupProf Frederick Ma, Chairman of HKTDC, discusses business resilience in Asia and promotes Hong Kong business advantages at the Singapore Regional Business Forum in BangkokPlease contact the HKTDC’s Communication & Public Affairs Department:Sam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China’s innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; CanSinoBIO) once again delivered a solid performance.According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly, with the reduction exceeding 94% compared to the same period last year. This reflects improved operational quality and lays a solid foundation for steady full-year growth. With core products selling strongly and multiple pipeline programs advancing, CanSinoBIO’s long-term growth story is steadily taking shape.Meningococcal Vaccine Portfolio Continues to Scale, Unlocking Growth DriversCanSinoBIO’s two currently marketed meningococcal conjugate vaccines—the quadrivalent meningococcal conjugate vaccine (MCV4, Menhycia) and the bivalent meningococcal conjugate vaccine (MCV2, Menphecia)—remain the company’s key revenue drivers. In particular, the sustained scaling-up of MCV4 demonstrates strong market competitiveness and is central to CanSinoBIO’s growth narrative.In 2024, Menhycia and Menphecia together generated nearly RMB 800 million in sales revenue, representing year-on-year growth of over 40%. In the first half of 2025, driven by deeper channel penetration and higher terminal market coverage, the sales of both vaccines continued to grow steadily. During the same period, the company’s meningococcal vaccine portfolio generated sales of over RMB 364 million, representing more than 38% year-on-year growth and providing a solid foundation for earnings.As the only MCV4 in China, Menhycia effectively covers four meningococcal serogroups, 'ACYW135', and leverages the high-safety CRM197 carrier protein technology. With outstanding clinical immunogenicity and safety, it has become the preferred choice for many parents seeking meningococcal vaccination for their children.Furthermore, Menhycia’s market potential is still being unlocked. The vaccine has been submitted to the National Medical Products Administration (NMPA) for an expanded age indication—from the current “children aged 3 months to 3 years (47 months)” to “children aged 3 months to 6 years (83 months).” If approved, this will directly broaden its coverage, strengthen penetration in the non-national immunization program market, and inject greater certainty into CanSinoBIO’s growth over the next two to three years, further consolidating the company’s leadership in the meningococcal vaccine field.iPneucia Officially Launched, a New Benchmark for Differentiated Pneumococcal VaccineIn June, CanSinoBIO’s self-developed product — the 13-valent pneumococcal conjugate vaccine (PCV13, iPneucia) — was officially approved for market launch, marking the company’s entry into the RMB 10 billion-plus pneumococcal vaccine market and the beginning of a new growth cycle.Pneumococcal diseases remain a serious global public health concern, with particularly high morbidity and mortality rates among children under five years old. Addressing the remaining immunization gaps in China, the launch of iPneucia fills the domestic technological void in high-end 13-valent pneumococcal conjugate vaccines, demonstrating CanSinoBIO’s leadership in differentiated innovation.Compared with existing competing products in the market, iPneucia achieves breakthroughs in three major dimensions. First, it offers more targeted protection, focusing on four high-risk serotypes—19F, 19A, 7F, and 3 - that together account for over 60% of pneumococcal disease cases among Chinese children. Clinical trial data show that its Geometric Mean Concentration (GMC) of antibodies is significantly higher than that of competing products. Second, in carrier protein technology, it adopts the globally pioneering CRM197+TT dual-carrier technology, overcoming the immune interference limitations of single-carrier vaccines. This both reduces the risk of immune suppression when co-administered with other vaccines and significantly enhances immunogenicity. Finally, in manufacturing safety, iPneucia uses an animal component - free fermentation process, reducing risks associated with animal-derived biological factors. It also employs no formaldehyde detoxification and adds no phenol during production, significantly improving vaccine safety.With these three advantages, iPneucia could potentially become another “ace” for CanSinoBIO in the infant bacterial vaccine market, following Menhycia. Notably, iPneucia shares a highly overlapping target population with Menhycia, creating strong channel synergies that will accelerate commercialization and enable the company to quickly capture market share in the RMB 10 billion-plus pneumococcal vaccine segment.Combination Vaccine Strategy Progresses SteadilyBeyond this, CanSinoBIO’s long-term potential lies in its continued build-out of a “Combination Vaccine” portfolio. Compared with traditional monovalent vaccines, multi-conjugate vaccine and polyvalent vaccine can prevent multiple diseases with a single injection, significantly improving vaccination efficiency and willingness - representing a key global direction in vaccine technology development.Following the quadrivalent vaccine Menhycia and multi-valent vaccine iPneucia, CanSinoBIO’s DTcP-Hib-MCV4 pentavalent vaccine—a representative combination vaccine—has attracted strong market attention. In February this year, it received clinical trial approval, marking a “zero-to-one” breakthrough for the company in the high-end combination vaccine sector.The DTcP-Hib-MCV4 pentavalent vaccine can simultaneously prevent pertussis, diphtheria, tetanus, Haemophilus influenzae type b (Hib) disease, and infection by the four meningococcal serogroups (ACYW135), achieving “protection against five diseases with a single shot”. This significantly reduces the number of injections and improves compliance among infants. More importantly, its core component Menhycia has already undergone commercial validation in China and enjoys a strong reputation, providing robust support for the combination vaccine’s development. This “point-to-surface” product upgrade logic enables CanSinoBIO to advance in the combination vaccine market with greater efficiency and confidence. With the government placing high importance on combination vaccine R&D and offering policy support, CanSinoBIO is well-positioned to capture this high-value market.R&D-Driven Growth with a Clear Product Pipeline and Strong ReservesWhile consolidating its existing market advantages, CanSinoBIO continues to strengthen its mid-to-long-term growth momentum through robust R&D capabilities and differentiated pipeline planning.Its DTcP for infants and young children has entered priority review and is expected to fill a domestic market gap. The Tdcp for people aged 6 years old and above has completed Phase III subject enrollment, enabling full life-cycle immunization coverage. The tetanus vaccine’s registration application has been accepted, and it is expected to offer superior safety and immunogenicity data compared with existing products. The Recombinant Poliomyelitis Vaccine, funded by Gates Foundation, has initiated clinical trials in Indonesia and has also received domestic clinical trial approval. Globally innovative Protein Based Pneumococcal Vaccine (PBPV) and inhaled tuberculosis vaccines have entered clinical research and proof-of-concept validation.The company has now built a rich pipeline covering multiple technology platforms and full life-cycle segments, including meningococcal vaccines, pneumococcal vaccines, diphtheria tetanus pertussis vaccine, polio vaccines, tuberculosis vaccines, and zoster vaccine. Several major products are entering critical stages of registration review or clinical trials. Meanwhile, CanSinoBIO’s continuous breakthroughs in key technology platforms support a strategic shift from reliance on single products to sustained pipeline output.Overall, in the first half of 2025, CanSinoBIO maintained the strong growth momentum seen since 2024, proving that its closed-loop capabilities from product R&D to commercialization have become increasingly mature. Against the backdrop of ongoing national policy support for innovative vaccines and domestic high-end vaccine substitution, CanSinoBIO — leveraging its solid R&D foundation, differentiated pipeline layout, and efficient commercialization execution—is accelerating the realization of its long-term growth potential and moving steadily toward becoming a global leader in innovative vaccines.CanSinoBIO, https://www.cansinotech.com [SSE:688185, HKG:6185, OTC:CASBF] Copyright 2025 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - August 20, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that it has entered into an agreement with Red Cloud Securities Inc. ("Red Cloud"), as sole underwriter and bookrunner, pursuant to which Red Cloud has agreed to purchase for resale 5,555,556 units of the Company (each, a "Unit") at a price of C$0.90 per Unit (the "Offering Price") on a "bought deal" basis in a public offering for gross proceeds of approximately C$5,000,000 (the "Underwritten Offering").Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to purchase one common share of the Company (each, a "Warrant Share") at a price of C$1.35 at any time on or before that date which is 36 months after the Closing Date (as herein defined).The Company has granted to the Underwriter an option (the "Over-Allotment Option", and together with the Underwritten Offering, the "Offering"), exercisable, in whole or in part, at any time for a period of up to 30 days after and including the Closing Date, to purchase for resale the number of additional Units equal to up to 15% of the number of Units sold pursuant to the Underwritten Offering at the Offering Price to cover over allotments, if any, and for market stabilization purposes.The net proceeds from the Offering will be used by the Company to fund ongoing operations including, but not limited to, commercial development, product development and working capital.In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement") to the Company's final short form base shelf prospectus dated March 7, 2025 (the "Shelf Prospectus"), with the securities regulatory authorities in each of the provinces and territories of Canada, except Quebec. The Units may also be sold in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and in such other jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction, and provided the issuance of the Units (including the underlying securities) is permitted under laws applicable to the Company (including the Australian Corporations Act 2001 (Cth).Copies of the Shelf Prospectus and the Supplement to be filed in connection with the Offering can be found on SEDAR+ at www.sedarplus.ca. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement, the Shelf Prospectus and the other documents the Company has filed on SEDAR+ at www.sedarplus.ca before making an investment decision.The Offering is expected to close on or about September 3rd, 2025 (the "Closing Date"), or on such date as agreed upon between the Company and Red Cloud. The closing of the Offering is subject to the Company receiving all necessary regulatory approvals, including the approval of the TSX Venture Exchange to list, on the Closing Date, the common shares of the Company issuable from the sale of Units as well as upon the exercise of the Warrants.This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.About GMGGMG is an Australian-based clean-technology company, which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in-house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low-cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy saving coating), which is now being marketed into other applications, including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium ion batteries.GMG's 4 critical business objectives are:Produce Graphene and Improve/Scale Cell Production ProcessesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the expected size and terms of the Offering, the anticipated timing of closing the Offering, the ability of the Company to satisfy all conditions to closing the Offering, and the expected use of proceeds from the Offering.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; that the Company will receive the necessary regulatory approvals for the Offering; use the proceeds from the Offering as anticipated; the Company's performance and general business and economic conditions.Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that the Company is not able to use the proceeds from the Offering as anticipated by management; the risk that the Company does not receive the requisite regulatory approvals for the Offering; overall economic conditions; technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward looking statements; the volatility of global capital markets; political instability; the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel; unexpected development and production challenges; unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263207 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Hengdeli Holdings Limited (“Hengdeli” or the “Company” and, together with its subsidiaries, the “Group”; stock code: 3389) announced its interim results for the six months ended 30 June 2025 ("the period under review"). In the first half of 2025, the global environment remained complex and volatile, with uncertainties such as increasing trade barriers, intensifying trade frictions and continuing geopolitical conflicts weighing on the momentum of global economic growth. Under these pressures, China’s economic growth slowed down but maintained stable amidst multiple domestic and external challenges. Still, the country's economy remained resilient as it carried on with steady and sound development. In the face of a complex and volatile operating environment, the Group has adapted its business to market changes by adhering to the principle of “sound, steady and long-term operations” in order to preserve its market position and pursue new opportunities as well as make every effort to safeguard the interests of its shareholders.During the review period, the Group recorded revenue of RMB314,314,000 (six months ended 30 June 2024: RMB580,361,000), representing a year-on-year decrease of 45.8%; high-end consuming accessories business recorded revenue of RMB248,095,000 (six months ended 30 June 2024: RMB352,339,000), representing a year-on-year decrease of 29.6%; commodity trading revenue amounted to RMB66,219,000 (six months ended 30 June 2024: RMB228,022,000), representing a year-on-year decrease of 71.0%. During the period under review, the Group recorded a profit of RMB26,033,000 (six months ended 30 June 2024: profit of RMB499,000), representing a year-on-year increase of 5,117.0%. Profit attributable to equity shareholders amounted to RMB26,308,000 (six months ended 30 June 2024: loss of RMB2,504,000), representing a year-on-year increase of 1,150.6%. The profit was mainly attributable to foreign exchange gains incurred by the operating units as a result of exchange rate fluctuations.During the period under review, in view of uncertainties in the international market and the slowdown in domestic economic growth, the Group’s high-end consuming accessories business continued to face pressure. The Group has taken various measures to cope with the complicated operating environment, and continued to broaden its business models, acquire new customers and develop new products through innovative approaches. At the same time, the Group has enhanced its technological innovation capabilities, accelerated its mechanization, and standardized and strengthened its information and automation management. All these measures have yielded effective results and improved our ability to cope with risks. During the period under review, the sales performance and profit of the high-end consuming accessories business both recorded year-on-year decreases due to the impact of the operating environment.In terms of international trading, during the period under review, the Group continued to carry out the international commodity trading business in line with its established strategy. The business mainly covers the importation of iron ore, thermal coal and coking coal to Mainland China. Global demand for iron ore grew at a slower pace and prices weakened due to dampening economic prospects as a result of trade frictions. Impacted by fluctuating decline in sales prices of ore sand and weakened customer purchasing intentions, the sales and gross profits of the international commodity trading business decreased as compared to the same period last year but still maintained profitability. The Group planned to establish a bulk cargo transshipment logistics park in Mexico integrating customs clearance, import, transportation and warehousing, and has initiated collaborations with and provided services to multiple large-scale enterprises and listed companies in China. In the second half of the year, the Group will continue to keep abreast of market dynamics, promptly and prudently carry out international commodity trading activities and explore new profit models and future development directions, in order to lay a solid foundation for the Group’s sustainable development.In terms of international shipping, during the period under review, the Group’s international shipping business mainly focused on the global maritime transportation of dry bulk cargo, such as coal, iron ore, manganese ore, bauxite, grain and industrial salt. Our clientele includes internationally renowned mining enterprises and large central state-owned enterprises and listed companies in China. During the period under review, the global dry bulk shipping market was volatile, which affected the freight rates. The Group closely monitored the market conditions, continued to expand its business by developing new customers and signing long voyage transportation contracts with its customers to lock in long-term profits for the Company. In the first half of the year, affected by market fluctuations, both the revenue and profit of the Group’s shipping business recorded a decline.At present, the international political and economic environment is experiencing increased turbulence, with trade barriers and trade frictions worsening. Facing this severe external environment, the economy of Mainland China is also encountering difficulties and challenges, including insufficient demand, sluggish consumption awaiting stimulation, and ongoing structural adjustments. Nevertheless, the economy of Mainland China has a stable foundation, strong resilience and great potential, and the long-term positive development trajectory remains unchanged. With the implementation and refinement of various policies and measures by the Chinese government, we maintain full confidence in the long-term sustainable economic growth of Mainland China.In the second half of the year, the Group will adhere to the principle of “sound, steady, and long-term operations”, and will leverage the stable business environment in Mainland China that “pursues stability while seeking progress” to keep abreast of the market trend and further advance the progress of international trade business prudently and steadily. Additionally, the Group will continuously expand the shipping business, which is closely related to international trade, and strive to become an important participant in the international shipping supply chain, so as to provide support for the breakthroughs in corporate development.The Group will also adapt to changing market demands and continuously enhance its integrated service capabilities in commercial space for both Mainland China and international markets. We will adjust the manufacturing of high-end accessories for renowned watches while promoting a limited number of diversified business activities and expanding high-end consuming accessories manufacturing to other high-end lifestyle products, such as jewellery, eyeglasses, cosmetics, mobile phones and other 3C products. Additionally, we will expand our commercial space beautification services to living space beautification services, thus becoming an indispensable and independent segment in the ecological chain of high-end consuming accessories. Copyright 2025 ACN Newswire via SeaPRwire.com.

Results Summary- Total revenue increased by 8% to HK$2,800 million, among which the revenue from Hong Kong increased by 9% to HK$1,600 million while the revenue from Mainland China increased by 9% to HK$700 million – both markets recorded growths- Revenue from the jewellery segment increased markedly by 13% to HK$1,100 million, among which gold products accounted for over 75% of the revenue from the jewellery segment- Gross profit rose by 8% to HK$800 million; gross profit margin remained resilient at 30.1%- Adjusted EBITD1 increased to HK$300 million and net profit rose by 5% to HK$200 million- As at 30 June 2025, bank balances and cash on hand amounted to over HK$1,500 million (31 December 2024: HK$950 million), without any bank borrowings and was in a net cash position, hence its net gearing ratio was zero, indicating a very healthy financial position- Successfully partnered with Mr. Chan Sai Cheong, strives to expand the jewellery business in Mainland China under “Emperor Jewellery”, and has already drawn up a preliminary roadmap for store expansions, with an initial target of 600 stores in Mainland China in the next five years; enables the jewellery business to become its future growth driver under the solid foundation of its watch business- Opened a Patek Philippe flagship store at a prime location in Central, Hong Kong, strengthening its market positionHONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Emperor Watch & Jewellery Limited (“Group” or “Emperor W&J”) (Stock code: 887), a leading retailer of European-made watches and jewellery products, announced its interim results for the six months ended 30 June 2025 (“Period”).In spite of market uncertainties and challenging business environment, the Group’s total revenue grew by 7.6% to HK$2,794 million (2024: HK$2,597 million) during the Period. Revenue from Hong Kong increased by 8.8% to HK$1,594 million (2024: HK$1,465 million), accounting for 57.1% (2024: 56.4%) of the total revenue, and the revenue from Mainland China increased by 8.7% to HK$723 million (2024: HK$665 million), accounting for 25.9% (2024: 25.6%) of the total revenue. In terms of revenue by product segment, the revenue from the watch segment increased by 4.2% to HK$1,700 million (2024: HK$1,632 million), accounting for 60.8% (2024: 62.8%) of the total revenue, and the revenue from the jewellery segment increased markedly by 13.4% to HK$1,094 million (2024: HK$965 million), accounting for 39.2% (2024: 37.2%) of the total revenue, among which gold products accounted for 75.2% (2024: 77.0%) of the revenue from the jewellery segment.The Group’s gross profit increased by 7.7% to HK$840 million (2024: HK$780 million) with gross profit margin remained resilient at 30.1% (2024: 30.0%). The Group’s net profit increased by 4.9% to HK$194 million (2024: HK$185 million) during the Period. Basic earnings per share was HK2.73 cents (2024: HK2.72 cents). The Board declares an interim dividend of HK0.55 cent (2024: HK0.65 cent) per share.As at 30 June 2025, bank balances and cash on hand of the Group amounted to HK$1,508 million (31 December 2024: HK$950 million), without any bank borrowings (31 December 2024: zero) and was in a net cash position, hence its net gearing ratio was zero (31 December 2024: zero), indicating a healthy financial position.During the Period, the Group successfully partnered with Mr. Chan Sai Cheong (“Mr. Chan”), an influential and highly respected jewellery industry veteran with over 40 years of experience, regarding strategic development of the Group’s jewellery business in Mainland China. The Group has drawn up a preliminary roadmap for store expansions in Mainland China, with an initial target of 600 stores in the next five years, opening in phases. During the first phase, the focus will be on opening stores targeting mid-to-high-end market segments in established first-tier and new first-tier cities; this will be followed by an emphasis on stores in second-tier cities, targeting mid-market segment.As at 30 June 2025, the Group had a total of 73 stores in Hong Kong, Macau, Mainland China, Singapore and Malaysia. During the Period, the Group opened two new jewellery stores, in Hong Kong and Macau. Additionally, a Patek Philippe flagship store and a Tudor watch boutique were opened in Hong Kong and Chongqing in Mainland China, respectively. Subsequent to the Period, the Group opened a jewellery store in Hangzhou, Mainland China.Ms. Cindy Yeung, Chairperson of Emperor W&J, said, “With the ongoing pick-up in foot traffic after the resumption of the multiple-entry Individual Visit Scheme for Shenzhen permanent residents, and the tourism blueprint launched by the Hong Kong government, the Group is confident that the overall retail market will further regain its growth momentum. The Patek Philippe flagship store that was recently opened by the Group in Hong Kong will further enhance the Group’s competitive edge in the luxury watch retail market and strengthens its market leading position.”Ms. Yeung concluded, “The Group expects that gold jewellery, as an alternative form of investment, will continue being well received by Chinese consumers, given the volatile property and stock markets. The Group considers the establishment of the strategic partnership with Mr. Chan is a valuable opportunity for expanding its jewellery business in Mainland China. We will effectively expand its retail network footprint with diversified market segmentation strategies, thereby capturing a substantial share of the enormous opportunities in the Mainland China market.”Financial Highlights For the six months ended 30 JuneChanges2024HK$ million2025HK$ millionTotal revenue2,5972,794+ 7.6%Gross profit780840+ 7.7%Gross profit margin30.0%30.1%+ 0.1ppAdjusted EBITD [1]282297+ 5.3%Net profit185194+ 4.9%Basic earnings per shareHK2.72 centsHK2.73 cents+ 0.4%[1] Adjusted EBITD represents earnings before interest, tax and depreciation charge on the self-owned flagship store, which reflects the Group’s core operating performanceAbout Emperor Watch & Jewellery LimitedWith long establishment history of over 80 years in Hong Kong since 1942, Emperor W&J (887.HK) is a leading retailer principally engages in the sale of European-made internationally renowned watches, and jewellery products under its own brand, “Emperor Jewellery”. Through its comprehensive watch dealership, unique marketing campaigns and extensive retail network at prime locations in Hong Kong, Macau, Mainland China, Singapore and Malaysia, Emperor W&J established a strong brand image amongst its target customers ranging from middle to high income groups worldwide. In recognition of its efforts in investor relations communications, Emperor W&J was granted with “Best IR Company” (Small Cap), “Best IR Team” (Small Cap) and “Best Investor Presentation Material” (Small cap) in HKIRA Investor Relations Awards 2025 by the Hong Kong Investor Relations Association. For more information, please visit its website: www.EmperorWatchJewellery.com.Investor/Media EnquiriesAnna LukGroup Investor Relations DirectorTel: +852 2835 6783Email: annaluk@emperorgroup.comJanice AuGroup Investor Relations ManagerTel: +852 2835 6799Email: janiceau@emperorgroup.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Novelty and inventiveness confirmed as Focus Graphite moves closer to securing patent for next-generation lithium-ion battery anode materialsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - August 20, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") is pleased to provide an update on the status of its patent application entitled "Advanced Anode Materials Comprising Spheroidal Additive-Enhanced Graphite Particles and Process for Making Same" (Canadian patent application No. 3,209,696).The Company reports that no further prior art has been cited in the examination process. The remaining requests for clarification from the examiner are minor in nature, primarily relating to formality issues in the description and figures. Focus is pleased with this outcome and has retained MBM Intellectual Property Law ("MBM") of Ottawa, ON, to prepare and submit claim amendments and expects a positive resolution.In support of its application, Focus has also received the International Preliminary Report on Patentability ("IPRP") issued during the Patent Cooperation Treaty ("PCT"). The IPRP confirmed that the Company's amended claims are both novel and inventive, strengthening the intellectual property protection around Focus' proprietary anode material technology.Additionally, the Company submitted amended claims under the Patent Prosecution Highway ("PPH") for the Canadian case. These amendments, which reduced the number of claims to avoid excess fees, form the basis for the Company's ongoing patent strategy.Dean Hanisch, Chief Executive Officer of Focus Graphite, commented, "This positive progress in our patent application process represents another important milestone in advancing Focus Graphite's downstream strategy. The recognition that our claims are both novel and inventive underscore the uniqueness of our technology and its potential to contribute meaningfully to next-generation lithium-ion battery anode materials."The Company will provide further updates as the application advances.About MBM Intellectual Property LawMBM is an independent, Canadian-owned boutique law firm dedicated exclusively to intellectual property law headquartered in Ottawa. For over 30 years, MBM has provided strategic IP advice and protection for clients ranging from start-ups and universities to multinational corporations. With a diverse team of patent and trademark agents, lawyers, and scientists, MBM manages global patent, trademark, and design portfolios and is recognized for delivering practical, cost-effective solutions. Proudly independent, MBM focuses on building long-term client relationships and maximizing the value of innovation.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated outcome of Focus Graphite's patent application process; the Company's ability to address and resolve the examiner's remaining objections; the expectation of securing patent protection for spheroidal additive-enhanced graphite materials; the potential strategic, commercial, and technological benefits of securing such intellectual property; and the advancement of the Company's downstream strategy to supply advanced graphite materials for lithium-ion batteries in North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263193 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 亨得利控股有限公司（「亨得利」或「公司」及其子公司「集團」，股票代號：3389）宣佈截至2025年6月30日止6個月（「回顧期內」）之中期業績。2025年上半年，全球環境依舊錯綜複雜，貿易壁壘增加、貿易摩擦加劇、地緣政治衝突等不確定性因素使全球經濟增長動能偏弱。中國經濟增速在內外多重挑戰中有所放緩，但仍實現穩定增長，體現了中國經濟的韌性，穩中向好的態勢得以繼續。面對複雜多變的經營環境，本集團以「行穩致遠」為準則，順應市場調整業務，保生存、求發展，努力維護股東的利益。回顧期內，本集團收入錄得314,314,000元（人民幣，下同；2024年6月30日止六個月為580,361,000元），較去年同期下降了45.8%；高端消費配套業務等收入為248,095,000元（2024年6月30日止六個月為352,339,000元），較去年同期下降了29.6%；大宗商品貿易收入為66,219,000元（2024年6月30日止六個月為228,022,000元），較去年同期下降了71.0%。於回顧期，本集團錄得溢利，溢利額為26,033,000元（截至2024年6月30日六個月溢利: 499,000元），較去年同期上升了5,117.0%；而股份持有人應佔溢利為26,308,000元（截至2024年6月30日六個月虧損：2,504,000元），較去年同期上升了1,150.6%。盈利的主要原因是匯率波動導致營運單位產生外匯兌換收益。回顧期內，面臨國際市場不確定性及國內經濟增長放緩，本集團高端消費配套業務發展持續承壓。集團採取多種措施應對複雜的經營環境，通過創新的方式，不斷拓寬業務模式，拓展新客戶，開發新產品。同時，提升技術創新水準，加快了機械化步伐；規範和加強資訊化及自動化管理。各項措施均取得了成效，提升應對風險的能力。回顧期內，由於經營環境因素影響，高端消費配套業務的銷售業績及利潤與去年同比均有所下降。國際貿易方面，回顧期內，本集團根據既定戰略繼續開展國際大宗商品貿易業務。業務範圍主要涵蓋鐵礦石、動力煤及焦煤向中國內地的進口。由於貿易摩擦衝擊經濟前景，全球鐵礦石需求增速放緩，價格疲軟。受礦砂銷售價格的波動下降及客戶購買意願減弱等因素的影響，國際大宗商品貿易業務之銷售額及毛利較去年同期均有所下滑，但仍然維持了正面營收。集團計劃於墨西哥建設的一個集清關、進口、運輸、倉儲於一體的大宗貨物中轉物流園區，已經與多個中國大型企業與上市公司展開合作並提供服務。下半年，集團將繼續緊跟市場動態，適時而謹慎地開展國際大宗商品貿易活動，尋求新的盈利模式和未來發展方向，為集團的健康生存與發展奠定堅實基礎。國際海運方面，回顧期內，集團國際海運業務主要專注於全球大宗乾散貨物的海洋運輸，貨種涵蓋煤炭、鐵礦石、錳礦石、鋁釩土、糧食及工業鹽等大宗貨物，服務的客戶包括國際知名礦山和中國大型中央企業及上市公司等。回顧期內，全球乾散貨航運市場波動大，運價受到影響。集團緊貼市場行情，繼續拓展業務，努力發展新客戶，與客戶致力於簽訂長航次運輸合同，為公司鎖定長期利潤。上半年，受市場波動的影響，集團海運業務收入與利潤均出現下滑。當前，國際政治、經濟環境動盪不安因素加劇，貿易壁壘和貿易摩擦形勢嚴峻。面對嚴峻的外部環境，中國內地經濟也面臨一定的困難和挑戰，需求端不足，消費端有待提振，結構性調整仍在持續。然而，中國內地經濟基礎穩、韌性強、潛能大，長期向好的發展趨勢未發生改變。隨著中國政府各項政策措施的實施與完善，對未來中國內地經濟長期持續發展態勢仍然充滿信心。下半年，本集團將堅持「行穩致遠、持續經營」之原則，依託中國內地「穩中求進、以進促穩」的經濟環境，緊貼市場，謹慎而穩妥地持續推進國際貿易業務，並不斷擴展與國際貿易密切相關的海運業務，力爭成為國際海運供應鏈中的重要一員，為企業的突破性發展提供助力。集團亦將順應市場需求，面向中國內地和國際雙市場，不斷提升商業空間一體化服務水準。我們將調整高端名表配套產品的生產，同時推進有限多元化業務，拓展高端消費配套生產至其他高端生活品領域，如珠寶、眼鏡、化妝品、手機及其他3C產品，並將商業空間美化服務擴展至生活空間美化服務，從而在高端消費配套生態鏈中成為不可或缺的獨立環節。 Copyright 2025 亞太商訊 via SeaPRwire.com.

業績摘要- 本期間的總收入上升8%至28億港元，其中來自香港的收入上升9%至16億港元，而來自中國內地的收入上升9%至7億港元，兩地均錄得增長- 珠寶分部的收入顯著上升13%至11億港元，當中黃金產品佔珠寶分部的收入超過7成半- 毛利增加8%至8億港元；毛利率為30.1%，表現呈抗跌力- 經調整EBITD1上升至3億港元，淨利潤增加5%至2億港元- 於2025年6月30日，銀行結餘及手頭現金為超過15億港元(2024年12月31日：9.5億港元)，沒有任何銀行借貸，並處於淨現金狀況，因此淨負債比率為零，反映財務狀況非常健康- 成功夥拍陳世昌先生，致力擴展「英皇珠寶」於中國內地之珠寶業務，並已擬定初步開店路線圖，初期目標是於未來五年分階段於中國內地開設600間店舖。在其具韌性的鐘錶業務基礎上，務求珠寶業務成為未來增長動力- 於香港中環黃金地段開設了一間百達翡麗旗艦店，進一步鞏固市場地位香港，2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 歐洲製鐘錶及珠寶首飾之零售商翹楚－英皇鐘錶珠寶有限公司(「本集團」或「英皇鐘錶珠寶」)(股份編號：887)公佈其截至2025年6月30日止六個月(「本期間」)之中期業績。縱使市場存在不明朗因素及營商環境充滿挑戰，本集團於本期間的總收入增加7.6%至27.9億港元(2024年：26.0億港元)。來自香港的收入增加8.8%至15.9億港元(2024年：14.7億港元)，佔總收入57.1%(2024年：56.4%)，而來自中國內地的收入增加8.7%至7.2億港元(2024年：6.7億港元)，佔總收入25.9% (2024年：25.6%)。按產品分部劃分的收入而言，鐘錶分部的收入上升4.2%至17.0億港元(2024年：16.3億港元)，佔總收入60.8% (2024年：62.8%)，而珠寶分部的收入顯著增加13.4%至10.9億港元(2024年：9.7億港元)，佔總收入39.2% (2024年：37.2%)，當中黃金產品佔珠寶分部的收入約75.2% (2024年：77.0%)。本集團的毛利增加7.7%至8.4億港元(2024年：7.8億港元)，毛利率為30.1% (2024年：30.0%)，表現呈抗跌力。本集團於本期間的淨利潤增加4.9%至1.94億港元(2024年：1.85億港元)。每股基本盈利為2.73港仙(2024年：2.72 港仙)。董事會宣派中期股息每股0.55港仙(2024年：0.65 港仙)。於2025年6月30日，本集團之銀行結餘及手頭現金為15.1億港元(2024年12月31日：9.5億港元)，沒有任何銀行借貸(2024年12月31日：零)並處於淨現金狀況，因此淨負債比率為零(2024年12月31日：零)，顯示健康的財務狀況。於本期間，本集團就其於中國內地珠寶業務之策略性發展成功夥拍陳世昌先生（「陳先生」）。陳先生為一位於珠寶行業具影響力且備受推崇的資深人士，擁有超過40年的經驗。本集團已初步擬定於中國內地擴展店舖的路線圖，初期目標是於未來五年分階段開設600 間店舖。於第一階段，開店的重點會落在成熟的一線城市及新一線城市，面向中高端市場；後續開店將側重於二線城市，面向中端市場。於2025年6月30日，本集團於香港、澳門、中國內地、新加坡及馬來西亞營運共73間店舖。於本期間，本集團於香港及澳門新開設兩間珠寶店，另外亦分別於香港及中國內地重慶開設一間百達翡麗旗艦店及一間帝舵表鐘錶專賣店。本期間後，本集團於中國杭州開設一間珠寶店。英皇鐘錶珠寶主席楊諾思女士表示︰「隨著深圳戶籍居民一簽多行個人遊計劃恢復後人流持續回升，加上香港政府推行的旅遊業藍圖，本集團有信心整體零售市場將進一步重拾增長動力。本集團近期於香港開業的百達翡麗旗艦店，將進一步提升本集團於名貴鐘錶零售市場的競爭優勢，並鞏固其市場領先地位。」楊女士總結道︰「鑒於物業及股票市場波動，本集團預期作為另類投資的黃金珠寶將繼續受中國消費者歡迎。本集團認為與陳先生建立戰略合作夥伴關係，將為擴展其於中國內地之珠寶業務帶來寶貴機會。我們將以多元化市場細分策略，有效地擴大其零售網絡佈局，從而在中國內地市場的龐大商機中搶佔重大份額。」財務亮點 截至6月30日止六個月變動2024年百萬港元2025年百萬港元總收入2,5972,794+ 7.6%毛利780840+ 7.7%毛利率30.0%30.1%+ 0.1百份點經調整EBITD [1]282297+ 5.3%淨利潤185194+ 4.9%每股基本盈利2.72港仙2.73港仙+ 0.4%[1] 經調整EBITD為利息、稅項及自家擁有旗艦店的折舊費用前之盈利，以反映本集團之核心營運表現關於英皇鐘錶珠寶有限公司作為零售商翹楚，英皇鐘錶珠寶(887.HK)自1942年在香港開業至今已有超過80年悠久歷史，業務包括銷售享譽國際之歐洲製腕錶及旗下「英皇珠寶」品牌之珠寶首飾。憑藉其代理齊全的鐘錶品牌、獨特的市場推廣策略以及遍佈香港、澳門、中國內地、新加坡及馬來西亞黃金地段的廣泛零售網絡，英皇鐘錶珠寶在全球各地中高收入人士的目標顧客群中已建立穩固的品牌形象。於香港投資者關係協會頒發的2025年香港投資者關係大獎中，英皇鐘錶珠寶榮獲「最佳投資者關係公司-小型股」、「最佳投資者關係團隊-小型股」及「最佳投資者關係素材-小型股」。有關詳細資料，請瀏覽其網站︰www.EmperorWatchJewellery.com。投資者/媒體查詢陸文靜集團投資者關係總監電話︰+852 2835 6783電郵：annaluk@emperorgroup.com區雪瑩集團投資人關係經理電話︰+852 2835 6799電郵：janiceau@emperorgroup.com Copyright 2025 亞太商訊 via SeaPRwire.com.

深圳, 2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 在本月早些時候備受期待的全球首秀之後，Level Infinite 將於11月初開啟《Rust Mobile》首次封閉測試。玩家們可以在 2025 年 8 月 20 日至 24 日於科隆舉辦的 gamescom 上，率先親身體驗這款遊戲。《Rust Mobile》將經典的開放世界生存玩法完整呈現，並針對行動裝置進行了優化，讓數百萬粉絲熟悉並熱愛的體驗隨時隨地都能上手。本作由 Facepunch Studios 官方授權，在忠實還原原作精神的同時，也為行動端帶來全新的生存方式。從收集資源、建造堅固基地，到殘酷的 PvP 戰鬥，以及伴隨信任與背叛而來的緊張氛圍，行動版完整呈現了《Rust》的核心精髓。玩家不僅能夠在 gamescom 上率先感受遊戲的魅力，還可透過即將到來的封閉測試進一步體驗其獨特樂趣。《Rust Mobile》亮相 2025 科隆遊戲展參展觀眾可前往 06.1 展館 - C-051G 展位，在這裡親身體驗遊戲，並參與一系列將《Rust》世界帶入現實的特色活動。活動包括與主題道具互動、沉浸式感受展位環境等。每位參與者都將獲得一次轉動「戰利品轉盤」的機會，有機會贏取 2025 科隆遊戲展獨家紀念品，包括限量版海報和環保袋。首次封閉測試將於今年11月開啟《Rust Mobile》首次封閉測試將於 2025 年 11 月初上線，屆時將邀請來自北美、西歐及部分亞洲地區的 30,000 名玩家參與。本次測試將提供四種語言版本：英語、日語、繁體中文和泰語，並支援 iOS、Android 及平板裝置，確保玩家能夠在自己熟悉的平台上暢玩遊戲。封閉測試現已開放註冊，玩家可前往 www.rustmobile.com 報名。欲了解更多有關《Rust Mobile》的資訊或進行預註冊，請訪問 rustmobile.com，或關注遊戲的 X 帳號與 YouTube 頻道。有關科隆遊戲展開館時間，請訪問 www.gamescom.global 。關於 Level InfiniteLevel Infinite 是騰訊旗下的全球遊戲品牌，致力於隨時隨地為全球玩家帶來引人入勝且獨具特色的遊戲體驗。該品牌還為全球範圍內的開發者和合作工作室提供多種服務與資源，幫助他們釋放遊戲潛力。Level Infinite 既是《PUBG MOBILE》《王者榮耀》《勝利女神：NIKKE》等爆款遊戲的發行商，也是《沙丘：覺醒》（Funcom 開發）、《戰鎚40K：Darktide》等眾多遊戲的深度合作夥伴。欲了解更多關於 Level Infinite 的資訊，請訪問 www.levelinfinite.com 。聯絡資訊Kirsty EndfieldSwipe Right PRtencent@swiperight.gg來源: Level Infinite Copyright 2025 亞太商訊 via SeaPRwire.com.

A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.